🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07536165
Starting soon Observational

Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke

NCT07536165 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Observational
Started
2026-04
Last updated
2026-04-17

Condition(s) studied

StrokeAcute Ischemic Stroke

Investigational drug(s) / intervention(s)

Tenecteplase →

Tenecteplase: Intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) administered as a single IV bolus over 5-10 seconds. In this observational cohort, tenecteplase is the only thrombolytic agent included and there is no active comparator.

Study summary

The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with acute ischemic stroke (AIS) in routine clinical practice across China.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * 1\. Age ≥ 18 years; * 2\. Clinical diagnosed of acute ischemic stroke; * 3\. Time from last known well (LKW) to initiation of intravenous thrombolysis \> 4.5 hours (including wake-up stroke and unwitnessed stroke); * 4\. Received intravenous tenecteplase; * 5\. Provided written informed consent. Exclusion Criteria: * 1\. Any condition judged by the investigator to make the participant unsuitable for study participation or follow-up (e.g., psychiatric disorders, cognitive impairment, or emotional disturbances).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong
Liuyang Jili Hospital Guankou Hunan

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536165 on ClinicalTrials.gov ↗ ← All trials in China